Urgently hiring an Aseptic/Biological Operator for a growing CDMO cell and gene therapy company!
Job Description:
Ensures that all work is carried out in compliance with company Safety Policies, GMP and SOPs.
Prepares for production run by reviewing the production schedule; identifying batch specific requirements; weighing and measuring ingredients and adding to mixing equipment.
Responsible to review all documentation including Batch records and Logbooks in “Real Time and Right First Time” and demonstrate error free documentations.
Shift: 7:00 am to 3 pm (M-F) with some weekend flexibility
Qualifications:
High school diploma with 1-3 years of experience within a pharmaceutical or biotechnology company.
Experience and/or understanding of aseptic gowning.
Experience working in a biological safety cabinet (BSC) - REQUIRED
Previous cell and gene therapy experience is preferred.
Why work here?
They are one of the fastest growing cell and gene therapy companies in the nation with the opportunity to grow with their expansion!
Diversity, Equity & Inclusion
At Actalent, diversity and inclusion are a bridge towards the equity and success of our people. DE&I are embedded into our culture through:
Hiring diverse talent
Maintaining an inclusive environment through persistent self-reflection
Building a culture of care, engagement, and recognition with clear outcomes
Ensuring growth opportunities for our people
Actalent is an equal opportunity employer.
About Actalent
Actalent connects passion with purpose. We help visionary companies advance their engineering and science initiatives through access to specialized experts that drive scale, innovation, and speed to market. With a network of almost 30,000 engineering and sciences consultants and more than 4,500 clients across the U.S., Canada, Asia, and Europe, Actalent serves many of the Fortune 500. An operating company of Allegis Group, the global leader in talent solutions, Actalent launched as a new specialized engineering and sciences services and workforce solutions brand in 2021.